In today’s briefing:
- 2025 (“Year of the Snake”) Major IPOs Pipeline in Korea
- A Review of Rights Offerings/Capital Raise Announcements in Korea in 2024
- ISU Petasys Ignores FSS: A Likely Short-Term Dip Sets up an Opportunity to Target 15% Discount
2025 (“Year of the Snake”) Major IPOs Pipeline in Korea
- This is our 10th “Annual Edition of the Major Korean IPOs Pipeline Preview” at Smartkarma.
- This insight will feature 50 of the biggest potential IPOs in Korea in 2025.
- These 50 IPOs in Korea are likely to represent more than 80% of all capital raised through IPOs in Korea next year.
A Review of Rights Offerings/Capital Raise Announcements in Korea in 2024
- In this insight, we review the major rights offerings/capital raises that were announced in Korea in 2024.
- In general, the major rights offerings/capital raises tend to result in lower share prices one month, three months, and over a longer time frame.
- There are some exceptions. Peptron and ABL Bio experienced higher share prices even after their capital raise announcements, especially after a longer time frame (3 months or more).
ISU Petasys Ignores FSS: A Likely Short-Term Dip Sets up an Opportunity to Target 15% Discount
- ISU Petasys is betting the FSS chief, tied to the current administration, won’t have much market power due to the impeachment drama—and that gamble looks likely to pay off.
- ISU Petasys’ rights offering still offers solid trade potential, with 97% stockholder allocation and only 21% from the major shareholder, increasing the chance of significant unclaimed shares hitting the market.
- Our plan is to grab stock rights cheap, ride the 15% discount, and capitalize on stock pullbacks, though lack of futures limits short hedging. Still, an unhedged setup looks promising.